Thematic Review Series: High Density Lipoprotein Structure, Function, and Metabolism Cardioprotective functions of HDLs

被引:223
作者
Rye, Kerry-Anne [1 ]
Barter, Philip J. [1 ]
机构
[1] Univ New S Wales, Lipid Res Grp, Ctr Vasc Res, Sydney, NSW 2052, Australia
基金
英国医学研究理事会;
关键词
cholesterol efflux; vascular inflammation; pancreatic beta cell function; oxidation; thrombosis; endothelial repair; endothelial function; angiogenesis; apoptosis; APOLIPOPROTEIN-A-I; SCAVENGER RECEPTOR-BI; ATP-BINDING CASSETTE; CELLULAR CHOLESTEROL EFFLUX; CORONARY-ARTERY-DISEASE; ENDOTHELIAL PROGENITOR CELLS; ESTER TRANSFER PROTEIN; ADHESION MOLECULE EXPRESSION; RANDOMIZED CONTROLLED-TRIAL; CYTOKINE-INDUCED EXPRESSION;
D O I
10.1194/jlr.R039297
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Multiple human population studies have established the concentration of high density lipoprotein (HDL) cholesterol as an independent, inverse predictor of the risk of having a cardiovascular event. Furthermore, HDLs have several well-documented functions with the potential to protect against cardiovascular disease. These include an ability to promote the efflux of cholesterol from macrophages in the artery wall, inhibit the oxidative modification of low density lipoproteins (LDLs), inhibit vascular inflammation, inhibit thrombosis, promote endothelial repair, promote angiogenesis, enhance endothelial function, improve diabetic control, and inhibit hematopoietic stem cell proliferation. There are undoubtedly other beneficial functions of HDLs yet to be identified. The HDL fraction in human plasma is heterogeneous, consisting of several subpopulations of particles of varying size, density, and composition. The functions of the different HDL subpopulations remain largely unknown. Given that therapies that increase the concentration of HDL cholesterol have varying effects on the levels of specific HDL subpopulations, it is of great importance to understand how distribution of different HDL subpopulations contribute to the potentially cardioprotective functions of this lipoprotein fraction. This review summarizes current understanding of the relationship of HDL subpopulations to their cardioprotective properties and highlights the gaps in current knowledge regarding this important aspect of HDL biology.
引用
收藏
页码:168 / 179
页数:12
相关论文
共 126 条
[1]   The roles of different pathways in the release of cholesterol from macrophages [J].
Adorni, Maria Pia ;
Zimetti, Francesca ;
Billheimer, Jeffrey T. ;
Wang, Nan ;
Rader, Daniel J. ;
Phillips, Michael C. ;
Rothblat, George H. .
JOURNAL OF LIPID RESEARCH, 2007, 48 (11) :2453-2462
[2]   PARENTAL HISTORY OF EARLY MYOCARDIAL-INFARCTION IS ASSOCIATED WITH DECREASED LEVELS OF LIPOPARTICLE-AI IN ADOLESCENTS [J].
AMOUYEL, P ;
ISOREZ, D ;
BARD, JM ;
GOLDMAN, M ;
LEBEL, P ;
ZYLBERBERG, G ;
FRUCHART, JC .
ARTERIOSCLEROSIS AND THROMBOSIS, 1993, 13 (11) :1640-1644
[3]   Factors influencing the ability of HDL to inhibit expression of vascular cell adhesion molecule-1 in endothelial cells [J].
Ashby, DT ;
Rye, KA ;
Clay, MA ;
Vadas, MA ;
Gamble, JR ;
Barter, PJ .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1998, 18 (09) :1450-1455
[4]   REGRESSION OF ATHEROSCLEROTIC LESIONS BY HIGH-DENSITY-LIPOPROTEIN PLASMA FRACTION IN THE CHOLESTEROL-FED RABBIT [J].
BADIMON, JJ ;
BADIMON, L ;
FUSTER, V .
JOURNAL OF CLINICAL INVESTIGATION, 1990, 85 (04) :1234-1241
[5]  
Baker PW, 1999, J LIPID RES, V40, P345
[6]  
Baker PW, 2000, J LIPID RES, V41, P1261
[7]   A MULTICENTER COMPARISON OF THE EFFECTS OF SIMVASTATIN AND FENOFIBRATE THERAPY IN SEVERE PRIMARY HYPERCHOLESTEROLEMIA, WITH PARTICULAR EMPHASIS ON LIPOPROTEINS DEFINED BY THEIR APOLIPOPROTEIN COMPOSITION [J].
BARD, JM ;
PARRA, HJ ;
CAMARE, R ;
LUC, G ;
ZIEGLER, O ;
DACHET, C ;
BRUCKERT, E ;
DOUSTEBLAZY, P ;
DROUIN, P ;
JACOTOT, B ;
DEGENNES, JL ;
KELLER, U ;
FRUCHART, JC .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1992, 41 (05) :498-503
[8]   HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events [J].
Barter, Philip ;
Gotto, Antonio M. ;
LaRosa, John C. ;
Maroni, Jaman ;
Szarek, Michael ;
Grundy, Scott M. ;
Kastelein, John J. P. ;
Bittner, Vera ;
Fruchart, Jean-Charles .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (13) :1301-1310
[9]   Effects of torcetrapib in patients at high risk for coronary events [J].
Barter, Philip J. ;
Caulfield, Mark ;
Eriksson, Mats ;
Grundy, Scott M. ;
Kastelein, John J. P. ;
Komajda, Michel ;
Lopez-Sendon, Jose ;
Mosca, Lori ;
Tardif, Jean-Claude ;
Waters, David D. ;
Shear, Charles L. ;
Revkin, James H. ;
Buhr, Kevin A. ;
Fisher, Marian R. ;
Tall, Alan R. ;
Brewer, Bryan .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (21) :2109-2122
[10]   Effect of Torcetrapib on Glucose, Insulin, and Hemoglobin A1c in Subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) Trial [J].
Barter, Philip J. ;
Rye, Kerry-Anne ;
Tardif, Jean-Claude ;
Waters, David D. ;
Boekholdt, S. Matthijs ;
Breazna, Andrei ;
Kastelein, John J. P. .
CIRCULATION, 2011, 124 (05) :555-562